Professor Colin Dayan talk on Type 1 diabetes screening and upcoming Teplizumab скачать в хорошем качестве

Professor Colin Dayan talk on Type 1 diabetes screening and upcoming Teplizumab

Professor Colin Dayan is an expert in diabetes and endocrinology based at Cardiff University. He is taking about autoimmunity in type 1 diabetes and role of new immune modulator like Teplizumab. Teplizumab is going to be a game-changer for type 1 diabetes management. It's the first FDA-approved drug that can delay the onset of clinical type 1 diabetes. Teplizumab is a monoclonal antibody that targets a specific protein (CD3) on T cells, essentially retraining them and stopping them from destroying the beta cells. Teplizumab is currently approved for patients aged 8 years and older with stage 2 type 1 diabetes. Stage 2 refers to the stage where the immune system is attacking the beta cells but blood sugar levels are still normal. Teplizumab treatment is a one-time course of daily infusions for 14 days. Studies have shown that teplizumab can delay the onset of clinical type 1 diabetes by up to 2 years.